Study summary
An inhaled drug built for a different lung disease cut lung function loss by more than three quarters
130.1 mLless lung function lost with treprostinil over a year
What was tested
Inhaled treprostinil, a drug already used for pulmonary artery hypertension, against placebo, mostly added on top of existing antifibrotic drugs.
What they found
- Lung function fell only 43.3 mL with treprostinil vs 196.2 mL with placebo over 52 weeks.
- Serious worsening events were 33% less common (hazard ratio 0.67).
- Cough was the main side effect (54.8% vs 33.1%), and more people stopped the drug because of side effects.
What it means
One of the largest effect sizes seen in an IPF trial; an inhaled route may add to standard pills rather than replace them.
Last reviewed 2026-11-14 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.